Company Recognition and Achievements - The company was awarded the "Top Power - Chinese Pharmaceutical High-Quality Development Achievement Enterprise" honor at the 33rd National Pharmaceutical Economic Information Conference, becoming one of the top 100 companies in the industry[6]. - The company has been recognized as a "Specialized, Refined, and New" small giant enterprise by Yunnan Province in February 2022[7]. - The company has been recognized as a provincial-level "Specialized, Refined, Characteristic, and Innovative" enterprise and is classified as a "Technology-based Small and Medium-sized Enterprise"[38]. Financial Performance - The company achieved a revenue of 128 million yuan in the first half of 2022, reflecting a year-on-year growth of 15%[12]. - The company's operating revenue for the current period is ¥282,475,007.03, a slight increase of 0.37% compared to the previous year[28]. - The net profit attributable to shareholders decreased significantly by 77.43% to ¥5,819,951.94 from ¥25,780,532.94 in the same period last year[28]. - The total assets at the end of the current period are ¥1,289,200,633.70, showing a decrease of 0.73% compared to the previous year[29]. - The total liabilities decreased by 6.58% to ¥217,680,195.20, while the net assets attributable to shareholders increased by 0.55% to ¥1,071,520,438.50[29]. - The gross profit margin for the current period is 79.80%, an increase from 78.92% in the previous year[28]. - The company's total liabilities increased, with accounts payable rising by 46.85% to ¥17.81 million[48]. - Total profit decreased by 73.89% year-on-year, significantly impacted by provisions for bad debts based on outstanding fund occupation balances[50]. Cash Flow and Financial Health - The net cash flow from operating activities turned negative at -¥127,133,552.01, a decline of 646.76% compared to the previous year[30]. - The company's cash and cash equivalents decreased by 57.32% to ¥133.93 million, primarily due to the payment of ¥155 million for capital occupation[46]. - The company reported a significant increase in financing receivables to ¥39,847,353.38 from ¥11,833,720.48 in the previous year[148]. - The company reported a net cash outflow from operating activities of CNY -127,133,552.01 in the first half of 2022, compared to a net inflow of CNY 23,252,214.86 in the same period of 2021[162]. Market Strategy and Product Development - The company is focusing on expanding its market presence by developing new sales channels, including third-party terminals, retail, and e-commerce[12]. - The company is committed to enhancing the quality of its products and building a high-level evidence chain for its Dan Zhan Hua series products[12]. - The company emphasizes the importance of product research as a key component of its competitive advantage[12]. - The company is actively involved in the promotion of clinical guidelines and expert consensus for its main products, with ongoing clinical research studies[39]. - The company plans to enhance its management level and reduce operational costs through a comprehensive review and optimization of human resources[39]. Risks and Challenges - The company reported a significant risk of price reduction for its products due to competitive bidding in the centralized procurement process, which may impact future growth and product margins[12]. - The company faced risks from market changes due to national medical reforms, particularly in centralized procurement, which may impact sales and profit margins[71]. - The company plans to diversify sales channels, including retail and e-commerce, to mitigate the impact of medical reform policies[71]. Shareholder and Management Commitments - The company has committed to distributing no less than 30% of the average distributable profit over the last three years in cash dividends, contingent upon meeting the conditions for cash dividend distribution[95]. - The actual controller and major shareholders are currently fulfilling their commitment to increase their holdings in the company’s stock, as outlined in the "Commitment Matters" section[93]. - The company has committed to not transferring or entrusting others with shares held by directors and senior management for twelve months following the listing on the selected tier[93]. - The company has implemented measures to address the financial occupation issue, including asset pledges from the controlling shareholder[88]. Corporate Governance and Compliance - The company has not violated any commitments regarding related party transactions during the reporting period[96]. - The company has maintained compliance with internal procedures regarding related party transactions and guarantees[82]. - The company has established a wastewater treatment system that meets the Class III discharge standards, ensuring compliance with environmental regulations[69]. - The company has conducted regular audits of suppliers to ensure product quality from the source[67]. Employee and Management Changes - The company appointed Chen Ying as the new CFO on June 30, 2022, succeeding He Yuan[135]. - Yang Zhiling was appointed as the new General Manager and Secretary of the Board due to operational development needs[135]. - The total number of employees at the end of the period is 479, with a decrease of 1 from the beginning of the period[138]. Share Capital and Ownership Structure - The company has a total share capital of 128 million shares, with the controlling shareholder being Shenzhen Jinsanjiang Investment Co., Ltd[22]. - The total number of unrestricted shares increased from 66,356,000 to 103,840,700, representing an increase from 51.84% to 81.13% of total shares[113]. - The number of shares held by the controlling shareholder decreased from 51,550,000 to 16,162,500, reducing their percentage from 40.27% to 12.63%[114]. Regulatory Compliance and Penalties - The company has received regulatory penalties and corrective measures from the China Securities Regulatory Commission for violations related to fund occupation[111]. - The company has pledged assets to secure the repayment of occupied funds, including equity stakes in various companies and receivables from government compensation[109].

Product Development and Innovation - The company's core product, Dengzhanhua Shengmai Capsule, was included in the "Guidelines for Diagnosis and Treatment of Ischemic Stroke at the Grassroots Level (2021)" by the Chinese Medical Association, highlighting its safety and efficacy[7] - The patent for a new compound, Dengzhanhua Xixin Acid Ethyl Ester, won the 22nd China Patent Excellence Award, showcasing the company's innovation capabilities[5] - The company is focused on expanding its market presence and developing new products, particularly in the field of ischemic cardiovascular and cerebrovascular disease medications[16] - The company is actively seeking collaborations with renowned universities and research institutions to bolster its research and development efforts[15] - The company aims to strengthen its product capabilities and develop new products based on existing research foundations[102] - The company is actively collaborating with top research institutions to enhance the efficacy and clinical application of its Danzhanhua series products[102] - The company is actively developing new products and conducting clinical research, including RCT studies for its core products, to strengthen its market access advantages[125] - The company plans to complete at least 3 patent applications related to the improvement of quality standards and the breeding of specialized varieties of the medicinal plant, Dan Zhan Hua[126] Financial Performance - The company's operating revenue for 2021 was RMB 566,174,666.68, representing a year-on-year increase of 25.45% compared to RMB 451,327,788.08 in 2020[30] - The net profit attributable to shareholders of the listed company for 2021 was RMB 83,485,272.59, an increase of 11.41% from RMB 74,937,077.58 in 2020[30] - The gross profit margin for 2021 was 80.01%, slightly up from 78.64% in 2020[30] - Total revenue for 2021 was 426,174,666.68 CNY, with a quarterly breakdown of 99,069,442.64 CNY in Q1, 182,355,796.47 CNY in Q2, 137,135,320.85 CNY in Q3, and 147,614,106.72 CNY in Q4[40] - The net profit growth rate for 2021 was 11.41%, compared to a decline of 17.80% in 2020[36] - The company's basic earnings per share for 2021 was 0.67, up 9.84% from 0.61 in 2020[30] - The company's current ratio improved to 12.43 in 2021, up from 9.77 in 2020, indicating better short-term financial health[33] - The cash flow from operating activities for 2021 was RMB 4,082,437.04, a significant decrease of 97.47% from RMB 161,074,720.50 in 2020[35] Market Position and Recognition - The company was recognized in the "Top 100 Chinese Traditional Chinese Medicine Enterprises" for the year 2020, indicating its strong market position[6] - The company has seven products in the "Dengzhanhua" series, with key products like "Dengzhan Shengmai Capsule" and "Dengzhan Xixin Injection" included in the national medical insurance catalog[48] - The company’s brand strength was rated at 15, with a brand value of 1.01558 billion yuan, ranking it on the Yunnan Brand Promotion Association's corporate brand value list[54] Operational Challenges and Risks - The company faces risks related to national medical and pharmaceutical reforms, including centralized procurement and price competition, which may impact sales in certain regions[14] - The company acknowledges the risk of losing core technical personnel, which could impact its long-term development and innovation capabilities[18] - The company faced challenges in 2021 due to the pandemic and economic recovery, emphasizing the need for compliance and cost management in the traditional Chinese medicine industry[52] - The company is preparing for the impact of the sixth batch of national centralized procurement, which is expected to accelerate market competition and reshape market rules[118] - The company has identified risks related to market dynamics, including price competition from centralized procurement, which could affect future growth and product margins[132] Compliance and Governance - The company has no significant audit issues, with the auditor issuing a standard report without reservations[104] - The company has committed to enhancing internal audit processes to monitor large fund transactions more effectively[153] - The company has implemented measures to strengthen governance and prevent future non-compliance regarding fund management[152] - The company has committed to ensuring that the cash dividends distributed in the last three years amount to no less than 30% of the average distributable profit achieved during that period[177] Future Plans and Strategies - The company plans to continue expanding its market presence and investing in new product development to drive future growth[74] - In 2022, the company plans to optimize channel integration and resource allocation, focusing on the "Shengmai" product line to increase sales and market coverage[124] - The company aims to enhance its product promotion efforts to quickly serve patients and create new profit growth points[50] - The company is focused on expanding its market presence through strategic partnerships and exploring new market opportunities in 2022[123] - The company will enhance organizational execution and resource allocation to achieve high-quality development while controlling costs within the annual budget framework[128]

Financial Performance - Operating revenue for the first quarter of 2022 was CNY 123,548,482.34, representing a growth of 24.71% year-on-year[14] - The net profit attributable to shareholders for the first quarter of 2022 was a loss of CNY 346,669.28, an improvement of 94.85% compared to the same period last year[14] - The basic earnings per share for the first quarter of 2022 was -CNY 0.003, showing a 94.00% improvement from -CNY 0.05 in the same period last year[14] - Total operating revenue for Q1 2022 reached ¥123,548,482.34, an increase of 24.8% compared to ¥99,069,442.64 in Q1 2021[64] - The net profit for Q1 2022 was CNY 1,587,375.91, a significant recovery from a net loss of CNY 6,409,723.97 in Q1 2021[69] - The total operating profit for Q1 2022 was CNY 1,997,371.15, a turnaround from an operating loss of CNY 4,262,917.11 in Q1 2021[68] - The company reported a total profit of CNY 1,971,184.07 in Q1 2022, compared to a loss of CNY 4,254,479.90 in Q1 2021, showcasing a strong recovery[68] Cash Flow - The net cash flow from operating activities decreased by 1,706.71% to -CNY 141,657,077.20, primarily due to increased cash outflows related to operating activities[16] - The net cash flow from operating activities was -161,121,783.84 CNY, compared to -5,090,915.71 CNY in the previous year, indicating a significant decline[74] - Total cash inflow from operating activities was 222,268,499.08 CNY, up from 139,318,686.37 CNY year-over-year, reflecting a growth of approximately 59.5%[75] - Cash outflow from operating activities totaled 383,390,282.92 CNY, compared to 144,409,602.08 CNY in the previous year, representing an increase of about 165.7%[75] - The net cash flow from investing activities was -16,706,130.00 CNY, compared to -9,529,078.93 CNY in the previous year, indicating a worsening investment position[74] - The total cash and cash equivalents at the end of the period were 66,053,954.03 CNY, down from 132,882,991.87 CNY year-over-year[75] - The company experienced a net decrease in cash and cash equivalents of -178,378,124.14 CNY during the period[75] Assets and Liabilities - The total assets as of March 31, 2022, were CNY 1,275,339,967.80, a decrease of 1.80% compared to the end of the previous year[14] - The company's debt-to-asset ratio (consolidated) was 16.47%, down from 17.94% at the end of the previous year[14] - Total liabilities decreased from ¥233,007,093.60 to ¥209,986,150.52, indicating a decline of about 9.9%[58] - Current liabilities decreased significantly from ¥64,804,460.71 to ¥38,970,619.57, a reduction of approximately 39.9%[58] - The company’s accounts receivable stood at CNY 184 million as of March 31, 2022, compared to CNY 197.33 million at the end of 2021[56] - The company’s inventory was valued at CNY 94.31 million as of March 31, 2022, slightly decreasing from CNY 95.85 million at the end of 2021[56] Shareholder Information - The number of common shareholders as of the report date was 9,431[21] - The company reported a total shareholding of 73,401,692 shares, representing 57.35% of the total shares[24] - Major shareholders include Shenzhen Jinsha River Investment Co., Ltd. with 30,000,000 shares (23.44%) and Lin Yanhe with 21,550,000 shares (16.84%)[24] - The total number of shares held by the top ten shareholders is 73,456,482, accounting for 57.35% of the total shares[24] Corporate Governance and Commitments - The company has committed to fully bear any costs related to social insurance and housing fund contributions for employees, ensuring no losses to the company[49] - The controlling shareholder will not misuse their position or interfere in the company's management, ensuring the protection of shareholder rights[47] - The company has committed to improving its profit distribution system to strengthen investor return mechanisms post-issuance[46] - The company has established measures for accountability in case of failure to fulfill commitments, including timely disclosures and compensation responsibilities[50] - The company has committed to reducing and regulating related party transactions, ensuring fair market practices and not seeking undue benefits from its shareholder position[48] Future Plans and Strategies - The company plans to engage in related transactions with Yunnan Biopharmaceutical Co., Ltd. not exceeding 1.2 million yuan for utility payments, with actual transactions amounting to 185,199.82 yuan[33] - The company announced plans to use up to 150 million yuan of idle funds for low-risk financial products, which positively impacted its financial performance[35] - The company aims to accelerate the investment progress of fundraising projects to achieve expected benefits sooner, enhancing shareholder returns[45] - The company will implement measures to mitigate the dilution of immediate returns from the public offering, including enhancing management efficiency and controlling expenses[44]